Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
Alessandro Mantovani, Gianluigi Zaza, Christopher D. Byrne, et al.
Metabolism (2017) Vol. 79, pp. 64-76
Open Access | Times Cited: 294

Showing 1-25 of 294 citing articles:

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 651
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, et al.
Diabetes Care (2018) Vol. 41, Iss. 8, pp. 1801-1808
Open Access | Times Cited: 496
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 443
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 355
NAFLD as a driver of chronic kidney disease
Christopher D. Byrne, Giovanni Targher
Journal of Hepatology (2020) Vol. 72, Iss. 4, pp. 785-801
Open Access | Times Cited: 347
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 261
MAFLD and risk of CKD
Dan‐Qin Sun, Yan Jin, Ting-Yao Wang, et al.
Metabolism (2020) Vol. 115, pp. 154433-154433
Open Access | Times Cited: 249
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
M Alexander, A. Katrina Loomis, Jolyon Fairburn-Beech, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 227
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway
Xiaopeng Zhu, Hua Bian, Liu Wang, et al.
Free Radical Biology and Medicine (2019) Vol. 141, pp. 192-204
Closed Access | Times Cited: 193
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 192
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery
Francesco Rubino, Ricardo V. Cohen, Geltrude Mingrone, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 7, pp. 640-648
Open Access | Times Cited: 167
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Ting-Yao Wang, Rui-Fang Wang, Zhi-Ying Bu, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 4, pp. 259-268
Open Access | Times Cited: 145
Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development
Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella
Nutrients (2021) Vol. 13, Iss. 5, pp. 1442-1442
Open Access | Times Cited: 139
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Eda Kaya, Yusuf Yılmaz
Journal of Clinical and Translational Hepatology (2021) Vol. 10, Iss. 2, pp. 329-338
Open Access | Times Cited: 120
The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury
Shahrbanoo Keshavarz Azizi Raftar, Fatemeh Ashrafian, Abbas Yadegar, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 2
Open Access | Times Cited: 109
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–2019
Bryan Chong, Gwyneth Kong, Kannan Shankar, et al.
Metabolism (2023) Vol. 141, pp. 155402-155402
Open Access | Times Cited: 96
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 3, pp. 386-403
Open Access | Times Cited: 55
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
Kai En Chan, Elden Yen Hng Ong, Charlotte Hui Chung, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 3, pp. 488-498.e14
Closed Access | Times Cited: 51
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 18
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
Arrigo F.G. Cicero, Alessandro Colletti, Stefano Bellentani
Nutrients (2018) Vol. 10, Iss. 9, pp. 1153-1153
Open Access | Times Cited: 153
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
Giuseppe Pugliese, Giuseppe Penno, Andrea Natali, et al.
Nutrition Metabolism and Cardiovascular Diseases (2019) Vol. 29, Iss. 11, pp. 1127-1150
Open Access | Times Cited: 141
Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis
Yan Liu, Guo‐Chao Zhong, Hao-Yang Tan, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 136
Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Alessandro Mantovani, Fabio Nascimbeni, Amedeo Lonardo, et al.
Thyroid (2018) Vol. 28, Iss. 10, pp. 1270-1284
Closed Access | Times Cited: 128
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
André Scheen
Diabetes & Metabolism (2019) Vol. 45, Iss. 3, pp. 213-223
Closed Access | Times Cited: 126
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, et al.
Metabolites (2020) Vol. 11, Iss. 1, pp. 22-22
Open Access | Times Cited: 103
Page 1 - Next Page

Scroll to top